Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Jenny Shan, Susan O'Brien, Neeli Reddy, William G. Wierda, Stefan Faderl, Guillermo Garcia-Manero, Srdan Verstovsek, Mary Beth Rios, Jorge Cortes

Research output: Contribution to journalArticlepeer-review

115 Scopus citations

Fingerprint Dive into the research topics of 'Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds